Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:55 2024-05-17 am EDT 5-day change 1st Jan Change
903.3 DKK -1.05% Intraday chart for Novo Nordisk A/S +2.28% +29.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genetic profile may predict best response to weight-loss drug Wegovy RE
Roche: share price stands out, Deutsche Bank in support CF
Health Care Flat as Momentum Wanes -- Health Care Roundup DJ
Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark MT
Novo Nordisk Building Under Construction at Manufacturing Hub in Denmark Hit by Fire MT
India's Biocon posts Q4 profit fall as higher raw material costs bite RE
NOVO NORDISK: FIRE AT KALUNDBORG SITE HAS NO IMPACT ON EXISTING… RE
Novo Nordisk building site hit by fire, Danish TV2 reports RE
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study MT
Roche shares gain on obesity drug results from early-stage trial RE
US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy MT
Health Care Up on Momentum -- Health Care Roundup DJ
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon MT
Sector Update: Health Care MT
Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says MT
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down RE
Novo Nordisk Owner to Buy Controlling Stake in Single Use Support MT
NOVO NORDISK : UBS sticks Neutral ZD
Health Care Up on Improved Risk Appetite -- Health Care Roundup DJ
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs RE
Novo Nordisk's Wegovy Reduces Cardiac Events, Sustains Weight Loss, New Analysis Shows MT
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal MT
NOVO NORDISK : JP Morgan reaffirms its Buy rating ZD
NOVO NORDISK : UBS reaffirms its Neutral rating ZD
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3 DKK
Average target price
909.2 DKK
Spread / Average Target
+0.66%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW